The latest review by the independent Data Safety Monitoring Committee of EyePoint (EYPT) pivotal Phase 3 DURAVYU program kept both LUGANO and LUCIA trials on course, with interim masked data indicating a continued favorable safety profile.

EyePoint’s recent safety update for DURAVYU comes after a sharp share price pullback this year, with the stock down 26.03% on a year to date share price return but still showing a 127.64% total shareholder return over the past 12 months as investors reassess both growth potential and trial risk.

If this kind of trial driven story has your attention, it can be worth widening your research to other healthcare companies working with AI driven approaches to treatment, using the 34 healthcare AI stocks

With EyePoint’s share price under pressure this year despite strong 1 year and 3 year total returns, investors now face a key question: is the current valuation overlooking future DURAVYU milestones or already reflecting them?

Most Popular Narrative: 65.1% Undervalued

At the last close of $12.93 versus a narrative fair value of $37.00, the current price sits well below what this widely followed model implies.

Investment in state of the art, scalable cGMP manufacturing capacity and disciplined cash management (cash runway into 2027) reduces operational risk, lowering the likelihood of further dilution and preserving future earnings and net margins as commercial sales ramp.

Curious what has to happen for that gap between price and fair value to close? Revenue expectations, margin shifts, and a punchy future earnings multiple sit at the core of this narrative.

Result: Fair Value of $37.00 (UNDERVALUED)

However, this hinges on a single lead asset, and any delay, setback or weaker than expected outcome in the DURAVYU programs could quickly challenge that undervalued thesis.

Another View: What If The Market Is Already Paying Up?

The narrative fair value suggests a large gap to today's $12.93 share price, yet the stock trades on a P/B of 4.7x versus 2.3x for the wider US Pharmaceuticals group and 2.4x for closer peers. That richer multiple implies less margin for error if DURAVYU stumbles, so which signal do you trust more?

For a closer look at what this richer book multiple might imply for valuation risk, tap into the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between risk and reward, it makes sense to move quickly, review the data for yourself, and weigh up the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If DURAVYU has sharpened your focus on stock selection, do not stop here. Use targeted screeners to spot opportunities that might otherwise slip past your watchlist.

• Zero in on companies that currently screen as attractively priced with solid fundamentals by running the 49 high quality undervalued stocks.
• Strengthen the defensive side of your portfolio by checking the 67 resilient stocks with low risk scores for stocks with more resilient profiles.
• Get ahead of the crowd by scanning the screener containing 21 high quality undiscovered gems before attention and liquidity potentially build.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.